Connor, Clark & Lunn Investment Management Ltd. Aclaris Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $28.9 Billion
- Q3 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 1,067,656 shares of ACRS stock, worth $2.69 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,067,656
Previous 797,134
33.94%
Holding current value
$2.69 Million
Previous $1.13 Million
79.31%
% of portfolio
0.01%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ACRS
# of Institutions
104Shares Held
81.7MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN14.3MShares$35.9 Million24.79% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$22.4 Million2.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.52MShares$16.4 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.28MShares$13.3 Million0.02% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.61MShares$11.6 Million0.59% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $168M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...